文献速递浆细胞疾病

Tabalumab(一种人源抗B细胞活化因子抗体)联合硼替佐米和地塞米松治疗既往接受过治疗的多发性骨髓瘤患者的2期研究

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.
PubMed 文献 · Br J Haematol · 2016-12-22

这项双盲2期研究将220例复发/难治性多发性骨髓瘤患者按1:1:1随机分配接受安慰剂、tabalumab 100 mg或300 mg联合地塞米松20 mg及皮下硼替佐米1.3 mg/m²(21天周期)。主要终点中位无进展生存期(mPFS)及次要疗效终点组间均无显著差异;低基线BAFF表达(n=162)患者mPFS显著长于高表达(n=55)患者。

要点

  • tabalumab 100 mg、300 mg与安慰剂组mPFS分别为6.6、7.5、7.6个月,组间无显著差异。
  • 最常见治疗中出现的不良事件为血小板减少(37%)、疲乏(37%)、腹泻(35%)、便秘(32%)。
  • 以75百分位为界,低基线BAFF表达患者mPFS显著长于高表达患者。

核心结论

  • 尽管tabalumab总体耐受良好,但联合治疗相比安慰剂未改善PFS;300 mg剂量相比100 mg未提高疗效;BAFF在多发性骨髓瘤患者中似乎具有一定预后价值。

研究设计与样本

  • 双盲2期研究,220例复发/难治性多发性骨髓瘤患者按1:1:1随机分配至安慰剂组(N=72)、tabalumab 100 mg组(N=74)或tabalumab 300 mg组(N=74),联合地塞米松20 mg及皮下硼替佐米1.3 mg/m²,21天为一周期。

主要发现

  • tabalumab 100 mg组、300 mg组与安慰剂组mPFS分别为6.6、7.5、7.6个月;tabalumab 100 mg vs 安慰剂HR(95%CI)=1.13(0.80-1.59),P=0.480;tabalumab 300 mg vs 安慰剂HR(95%CI)=1.03(0.72-1.45),P=0.884。
  • 最常见治疗中出现的不良事件为血小板减少(37%)、疲乏(37%)、腹泻(35%)、便秘(32%)。
  • 以75百分位为界,低基线BAFF(亦称TNFSF13B)表达患者(n=162)mPFS(95%CI)=8.3(7.0-9.3)个月,高表达患者(n=55)mPFS(95%CI)=5.8(3.7-6.6)个月,HR(95%CI)=1.59(1.11-2.29),P=0.015。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this double-blind, Phase 2 study, 220 patients with relapsed/refractory multiple myeloma were randomly assigned 1:1:1 to receive placebo (N = 72), tabalumab 100 mg (N = 74), or tabalumab 300 mg (N = 74), each in combination with dexamethasone 20 mg and subcutaneous bortezomib 1·3 mg/m2 on a 21-day cycle. No significant intergroup differences were observed among primary (median progression-free survival [mPFS]) or secondary efficacy outcomes. The mPFS was 6·6, 7·5 and 7·6 months for the tabalumab 100, 300 mg and placebo groups, respectively (tabalumab 100 mg vs. placebo Hazard ratio (HR) [95% confidence interval (CI)] = 1·13 [0·80-1·59], P = 0·480; tabalumab 300 mg vs. placebo HR [95% CI] = 1·03 [0·72-1·45], P = 0·884). The most commonly-reported treatment-emergent adverse events were thrombocytopenia (37%), fatigue (37%), diarrhoea (35%) and constipation (32%). Across treatments, patients with low baseline BAFF (also termed TNFSF13B) expression (n = 162) had significantly longer mPFS than those with high BAFF expression (n = 55), using the 75th percentile cut-off point (mPFS [95% CI] = 8·3 [7·0-9·3] months vs. 5·8 [3·7-6·6] months; HR [95% CI] = 1·59 [1·11-2·29], P = 0·015). Although generally well tolerated, PFS was not improved during treatment with tabalumab compared to placebo. A higher dose of 300 mg tabalumab did not improve efficacy compared to the 100 mg dose. Nonetheless, BAFF appears to have some prognostic value in patients with multiple myeloma.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Raje NS, Moreau P, Terpos E, et al. Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. Br J Haematol. 2016. PMID: 28005265. doi:10.1111/bjh.14483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。